The Pertussis Vaccine segmentation by application distinguishes three primary usage groups: infant immunization, adolescent booster, and maternal immunization. Infant immunization, administered as part of the primary DTaP series, dominates the market because national immunization programs target children under five, generating the largest volume of doses and accounting for roughly 55 % of total revenue. The adolescent booster, typically delivered as Tdap, supports school‑entry requirements and catch‑up schedules; its higher price per dose and expanding school‑based campaigns contribute about 25 % of market value. Maternal immunization, introduced to protect newborns through trans‑placental antibody transfer, is gaining traction in high‑income regions, driven by updated clinical guidelines; it represents an estimated 20 % of the market and is expected to grow faster than the other segments. Collectively, these application categories shape demand patterns, pricing dynamics, and forecasted growth across the global Pertussis Vaccine market. Regulatory approvals and reimbursement policies further differentiate the revenue potential of each application, reinforcing the strategic importance of targeting high‑growth segments.
